JP2013515490A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515490A5
JP2013515490A5 JP2012546239A JP2012546239A JP2013515490A5 JP 2013515490 A5 JP2013515490 A5 JP 2013515490A5 JP 2012546239 A JP2012546239 A JP 2012546239A JP 2012546239 A JP2012546239 A JP 2012546239A JP 2013515490 A5 JP2013515490 A5 JP 2013515490A5
Authority
JP
Japan
Prior art keywords
lactic acid
composition
acid bacterium
antigen
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012546239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515490A (ja
Filing date
Publication date
Priority claimed from PCT/US2010/041792 external-priority patent/WO2011008735A1/en
Application filed filed Critical
Priority claimed from PCT/US2010/062034 external-priority patent/WO2011079282A1/en
Publication of JP2013515490A publication Critical patent/JP2013515490A/ja
Publication of JP2013515490A5 publication Critical patent/JP2013515490A5/ja
Pending legal-status Critical Current

Links

JP2012546239A 2009-12-23 2010-12-23 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護 Pending JP2013515490A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28966309P 2009-12-23 2009-12-23
US61/289,663 2009-12-23
USPCT/US2010/041792 2010-07-13
PCT/US2010/041792 WO2011008735A1 (en) 2009-07-13 2010-07-13 Oral vaccines produced and administered using edible micro-organism
PCT/US2010/062034 WO2011079282A1 (en) 2009-12-23 2010-12-23 Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules

Publications (2)

Publication Number Publication Date
JP2013515490A JP2013515490A (ja) 2013-05-09
JP2013515490A5 true JP2013515490A5 (OSRAM) 2014-02-06

Family

ID=44196157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546239A Pending JP2013515490A (ja) 2009-12-23 2010-12-23 組み換え型乳酸連鎖球菌のミニカプセルの経口投与による免疫保護

Country Status (4)

Country Link
EP (1) EP2515661A4 (OSRAM)
JP (1) JP2013515490A (OSRAM)
CN (1) CN102665422B (OSRAM)
WO (1) WO2011079282A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9452205B2 (en) * 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
CN102965388A (zh) * 2012-12-07 2013-03-13 山东信得科技股份有限公司 一种表达猪传染性胃肠炎病毒基因工程菌制备方法
MX387331B (es) * 2014-04-10 2025-03-18 Riken Composiciones y metodos para induccion de celulas th17.
CN104587458B (zh) * 2014-12-04 2017-01-04 吉林医药学院 预防贾第虫病的二价dna疫苗及其肠溶制剂
CN110511399B (zh) * 2019-07-26 2022-03-04 广西大学 一种控释型纳米纤维素抗菌微凝胶的制备方法
CN116083240B (zh) * 2023-04-07 2023-08-29 深圳市第二人民医院(深圳市转化医学研究院) 工程化细菌及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2278358B (en) * 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
CN1120310A (zh) * 1993-03-11 1996-04-10 塞科雷泰克公司 在粘膜表面转运免疫原的聚合粘膜粘合剂
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
DE69942774D1 (de) * 1999-02-26 2010-10-28 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
CN1997352B (zh) * 2004-06-17 2010-12-01 天野酶制品美国有限公司 含粘膜粘附性聚合物的酶、微生物和抗体的控释制剂
EP2010210A4 (en) * 2006-04-21 2010-07-21 Dow Agrosciences Llc VACCINE AGAINST BIRD FLUID AND METHOD OF APPLICATION THEREFOR
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
KR101245604B1 (ko) * 2007-11-13 2013-03-21 메리테이지 파마, 인크. 코르티코스테로이드 조성물

Similar Documents

Publication Publication Date Title
Grant et al. Human influenza viruses and CD8+ T cell responses
Altenburg et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases
JP2013515490A5 (OSRAM)
JP2014507482A5 (OSRAM)
JP2013216685A5 (OSRAM)
JP2012126742A5 (OSRAM)
JP2011250797A5 (OSRAM)
JP2012176990A5 (OSRAM)
JP2008044945A5 (OSRAM)
CN109563492A (zh) 突变的病毒、其制备方法和应用
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
CN104232594B (zh) 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用
Banner et al. The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development
Peng et al. Boosted influenza-specific T cell responses after H5N1 pandemic live attenuated influenza virus vaccination
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
Lakdawala et al. Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets
JP2014511856A5 (OSRAM)
CN109790123A (zh) 新型衣壳蛋白装配抑制剂
JP2010506926A5 (OSRAM)
Moise et al. T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response
Zhang et al. Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus
HRP20171697T1 (hr) Varijanta hiv gp-120
JP2014502143A5 (OSRAM)
JP2016529316A5 (OSRAM)
Qin et al. PA-X protein of H1N1 subtype influenza virus disables the nasal mucosal dendritic cells for strengthening virulence